## IQV: IQVIA Holdings Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.96 indicates fundamental undervaluation. Quality metrics strong (ROE 19%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-4.5% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($216.18)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. IQVIA (NYSE: IQV) names AWS preferred agentic cloud to power new AI platform**
- Source: Stock Titan | 20251202T080000 | Bullish | Relevance: 100%
- IQVIA (NYSE: IQV) announced a strategic collaboration with Amazon Web Services (AWS), naming AWS as its Preferred Agentic Cloud Provider. This partnership aims to revolutionize clinical trial automation, medical affairs, and analytics in life sciences by deploying IQVIA's AI platform on AWS. The collaboration seeks to democratize AI for life sciences, accelerate drug innovation, and improve patient outcomes globally.

**2. IQVIA Holdings stock rating assumed at Overweight by Morgan Stanley**
- Source: Investing.com India | 20251202T033600 | Bullish | Relevance: 100%
- Morgan Stanley has initiated coverage of IQVIA Holdings (NYSE:IQV) with an Overweight rating and a price target of $265.00, citing expected strong demand for clinical stage CRO work and the company's leading position in diversified end markets. This positive outlook is supported by a significant 63.91% price return over the past six months and aligns with other analyst upgrades, despite some valuation concerns.

**3. IQVIA Holdings stock rating assumed at Overweight by Morgan Stanley**
- Source: Investing.com | 20251201T170500 | Bullish | Relevance: 100%
- Morgan Stanley initiated coverage on IQVIA Holdings (NYSE:IQV) with an Overweight rating and a price target of $265.00, suggesting a 16% upside. The firm anticipates strong demand for clinical research organization (CRO) work and highlighted IQVIA's leading position in diversified markets through its Technology & Analytics Solutions (TAS). This positive outlook is supported by recent upward revisions in earnings estimates by other analysts and the company's strong stock performance.

**4. Brandes Investment Partners LP Acquires New Position in IQVIA Holdings Inc. $IQV**
- Source: MarketBeat | 20251203T201007 | Bullish | Relevance: 100%
- Brandes Investment Partners LP has acquired a new position in IQVIA Holdings Inc. (NYSE:IQV), purchasing 18,489 shares valued at approximately $2.914 million in the second quarter. Other institutional investors have also adjusted their stakes in IQVIA, which now has about 89.62% institutional ownership. IQVIA recently reported strong quarterly earnings, beating analyst expectations, and provided optimistic guidance for FY2025.

**5. Morgan Stanley Raises Price Target on IQVIA Holdings to $265 From $250, Keeps Overweight Rating**
- Source: MarketScreener | 20251202T115200 | Bullish | Relevance: 100%
- Morgan Stanley has increased its price target for IQVIA Holdings (IQV) to $265 from $250, while maintaining an "Overweight" rating on the stock. This adjustment reflects continued positive sentiment from analysts towards the company, with other firms also recently raising their price targets. The article also provides key financial and operational details about IQVIA Holdings.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $265 | $250 | +6% |
| 2025-11-13 | BMO Capital | $260 | $0 | 0% |
| 2025-11-03 | TD Cowen | $215 | $206 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |
| 2025-11-13 | BMO Capital | init | Outperform |
| 2025-11-03 | TD Cowen | down | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($1.46M) |
| Sells | 2 ($4.59M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.9%)
- Blackrock Inc.: 8.7% (+4.5%)
- Harris Associates L.: 6.7% (-3.1%)
- State Street Corpora: 4.4% (-1.0%)
- JPMORGAN CHASE & CO: 3.9% (+110.0%)

### Key Risks

1. Insider selling cluster: $4.6M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.96 indicates undervaluation relative to growth. Analyst sentiment positive (2 raises, avg +5%). Insider selling cluster ($4.6M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.6B |
| Beta | 1.37 |
| 52W Range | $134.65 - $234.30 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.96 |
| Forward P/E | 17.6 |
| Current P/E | 19.1 |
| YoY Growth | 8.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.3% to 0.8% (-4.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.2pp (needs >4.0% for momentum thesis). MRS_5 (-1.1%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +DUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.80% (CS: 59) | Neutral |
| RSI_14 | 61.6 | Neutral |
| MACD Histogram | 0.05 | Bullish |
| vs SMA20 | 1.027x | Above |
| vs SMA50 | 1.074x | Above |
| vs SMA200 | 1.261x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $227.24
- **Stop Loss:** $216.18 (4.9% risk)
- **Target:** $249.36 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 85
- **Position Value:** $19,315.40
- **Portfolio %:** 19.32%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-05 (Est: $3.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.98 | $3.00 | +0.8% |
| 2025Q2 | $2.77 | $2.81 | +1.4% |
| 2025Q1 | $2.63 | $2.70 | +2.6% |
| 2024Q4 | $3.11 | $3.12 | +0.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*